Simon Hall
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Simon Hall has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Adam C. Reese
Department of Urology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA
2 shared publications - Alexander Kutikov
Fox Chase Cancer Center, Philadelphia, USA
2 shared publications - Allison Marziliano
Northwell Health
2 shared publications - Curtis Miyamoto
Temple Univ Hlth Syst, Fox Chase Canc Ctr, Dept Radiat Oncol, Philadelphia, PA USA
2 shared publications - Emmanuel Lapitan
Department of Psychology, Rowan University, 201 Mullica Hill Road, Robinson Hall 116G, Glassboro, NJ, 08028, USA
2 shared publications - Eric M. Horwitz
Fox Chase Cancer Center, Philadelphia, PA
2 shared publications
Latest Publications
- Open Access
- 27 February 2023
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 25, e46552
Preference Elicitation and Treatment Decision-Making among Men Diagnosed with Prostate Cancer: Results from the Healium Trial (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Elicitation of patients’ preferences is an integral part of shared decision making, the recommended approach for prostate cancer decision making. However, existing decision aids for this population do not specifically focus on patients’ preferences. Healium is a brief interactive web-based decision aid that aims to elicit patient’s treatment preferences and is designed for a low health literate population. Objective: This study used a randomized controlled trial to evaluate whether Healium (designed to target preference elicitation) is as efficacious as Healing Choices (a comprehensive education and decision tool) in improving outcomes for decision-making and emotional quality of life. Methods: Patients diagnosed with localized prostate cancer who had not yet made a treatment decision were randomly assigned to the brief Healium intervention or Healing Choices, an extensive decision aid previously developed by our group that serves as a virtual information center on prostate cancer diagnosis and treatment. Assessments were completed at baseline, 6-weeks and 3-months post-baseline, and included decisional outcomes (decisional conflict, satisfaction with decision, preparation for decision-making), and emotional quality of life (anxiety/tension and depression), along with demographics, comorbidities, and health literacy. Results: N = 327 individuals consented to participate in the study (171 were randomized to the Healium intervention arm and 156 were randomized to Healing Choices). The majority of the sample was non-Hispanic (96%), White (76%), married (78.4%), and had an average age of 62.4 years old (SD = 6.9). Within both arms, there was a significant decrease in decisional conflict from baseline to 6-weeks post baseline (Healium, P = <.001; Healing Choices, P = <.001), and a significant increase in satisfaction with one’s decision from 6 weeks to 3 months (Healium, P = .04; Healing Choices, P = .01). Within both arms, anxiety/tension (Healium, P = .23; Healing Choices, P = .27) and depression (Healium, P = .001; Healing Choices, P = <.001) decreased from baseline to 6-weeks, but only in the case of depression was the decrease statistically significant. Conclusions: Healium, our brief decision aid focusing on treatment preference elicitation, is as successful in reducing decisional conflict as our previously tested comprehensive decision aid, Healing Choices, and has the added benefit of brevity and the potential for integration into the physician consultation and electronic medical record. Clinical Trial: ClinicalTrials.gov NCT05800483; https://clinicaltrials.gov/ct2/show/NCT05800483
- 27 February 2023
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 25, e46552
Open AccessPreference Elicitation and Treatment Decision-Making among Men Diagnosed with Prostate Cancer: Results from the Healium Trial (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Elicitation of patients’ preferences is an integral part of shared decision making, the recommended approach for prostate cancer decision making. However, existing decision aids for this population do not specifically focus on patients’ preferences. Healium is a brief interactive web-based decision aid that aims to elicit patient’s treatment preferences and is designed for a low health literate population. Objective: This study used a randomized controlled trial to evaluate whether Healium (designed to target preference elicitation) is as efficacious as Healing Choices (a comprehensive education and decision tool) in improving outcomes for decision-making and emotional quality of life. Methods: Patients diagnosed with localized prostate cancer who had not yet made a treatment decision were randomly assigned to the brief Healium intervention or Healing Choices, an extensive decision aid previously developed by our group that serves as a virtual information center on prostate cancer diagnosis and treatment. Assessments were completed at baseline, 6-weeks and 3-months post-baseline, and included decisional outcomes (decisional conflict, satisfaction with decision, preparation for decision-making), and emotional quality of life (anxiety/tension and depression), along with demographics, comorbidities, and health literacy. Results: N = 327 individuals consented to participate in the study (171 were randomized to the Healium intervention arm and 156 were randomized to Healing Choices). The majority of the sample was non-Hispanic (96%), White (76%), married (78.4%), and had an average age of 62.4 years old (SD = 6.9). Within both arms, there was a significant decrease in decisional conflict from baseline to 6-weeks post baseline (Healium, P = <.001; Healing Choices, P = <.001), and a significant increase in satisfaction with one’s decision from 6 weeks to 3 months (Healium, P = .04; Healing Choices, P = .01). Within both arms, anxiety/tension (Healium, P = .23; Healing Choices, P = .27) and depression (Healium, P = .001; Healing Choices, P = <.001) decreased from baseline to 6-weeks, but only in the case of depression was the decrease statistically significant. Conclusions: Healium, our brief decision aid focusing on treatment preference elicitation, is as successful in reducing decisional conflict as our previously tested comprehensive decision aid, Healing Choices, and has the added benefit of brevity and the potential for integration into the physician consultation and electronic medical record. Clinical Trial: ClinicalTrials.gov NCT05800483; https://clinicaltrials.gov/ct2/show/NCT05800483
- Open Access
- 27 February 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Preference Elicitation and Treatment Decision-Making Among Men Diagnosed With Prostate Cancer: Randomized Controlled Trial Results of Healium (Preprint)
BACKGROUND Elicitation of patients’ preferences is an integral part of shared decision-making, the recommended approach for prostate cancer decision-making. Existing decision aids for this population often do not specifically focus on patients’ preferences. Healium is a brief interactive web-based decision aid that aims to elicit patients’ treatment preferences and is designed for a low health literate population. OBJECTIVE This study used a randomized controlled trial to evaluate whether Healium, designed to target preference elicitation, is as efficacious as Healing Choices, a comprehensive education and decision tool, in improving outcomes for decision-making and emotional quality of life. METHODS Patients diagnosed with localized prostate cancer who had not yet made a treatment decision were randomly assigned to the brief Healium intervention or Healing Choices, a decision aid previously developed by our group that serves as a virtual information center on prostate cancer diagnosis and treatment. Assessments were completed at baseline, 6 weeks, and 3 months post baseline, and included decisional outcomes (decisional conflict, satisfaction with decision, and preparation for decision-making), and emotional quality of life (anxiety/tension and depression), along with demographics, comorbidities, and health literacy. RESULTS A total of 327 individuals consented to participate in the study (171 were randomized to the Healium intervention arm and 156 were randomized to Healing Choices). The majority of the sample was non-Hispanic (272/282, 96%), White (239/314, 76%), married (251/320, 78.4%), and was on average 62.4 (SD 6.9) years old. Within both arms, there was a significant decrease in decisional conflict from baseline to 6 weeks postbaseline (Healium, P≤.001; Healing Choices, P≤.001), and a significant increase in satisfaction with one’s decision from 6 weeks to 3 months (Healium, P=.04; Healing Choices, P=.01). Within both arms, anxiety/tension (Healium, P=.23; Healing Choices, P=.27) and depression (Healium, P=.001; Healing Choices, P≤.001) decreased from baseline to 6 weeks, but only in the case of depression was the decrease statistically significant. CONCLUSIONS Healium, our brief decision aid focusing on treatment preference elicitation, is as successful in reducing decisional conflict as our previously tested comprehensive decision aid, Healing Choices, and has the added benefit of brevity, making it the ideal tool for integration into the physician consultation and electronic medical record. CLINICALTRIAL ClinicalTrials.gov NCT05800483; https://clinicaltrials.gov/study/NCT05800483
- 27 February 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessPreference Elicitation and Treatment Decision-Making Among Men Diagnosed With Prostate Cancer: Randomized Controlled Trial Results of Healium (Preprint)
BACKGROUND Elicitation of patients’ preferences is an integral part of shared decision-making, the recommended approach for prostate cancer decision-making. Existing decision aids for this population often do not specifically focus on patients’ preferences. Healium is a brief interactive web-based decision aid that aims to elicit patients’ treatment preferences and is designed for a low health literate population. OBJECTIVE This study used a randomized controlled trial to evaluate whether Healium, designed to target preference elicitation, is as efficacious as Healing Choices, a comprehensive education and decision tool, in improving outcomes for decision-making and emotional quality of life. METHODS Patients diagnosed with localized prostate cancer who had not yet made a treatment decision were randomly assigned to the brief Healium intervention or Healing Choices, a decision aid previously developed by our group that serves as a virtual information center on prostate cancer diagnosis and treatment. Assessments were completed at baseline, 6 weeks, and 3 months post baseline, and included decisional outcomes (decisional conflict, satisfaction with decision, and preparation for decision-making), and emotional quality of life (anxiety/tension and depression), along with demographics, comorbidities, and health literacy. RESULTS A total of 327 individuals consented to participate in the study (171 were randomized to the Healium intervention arm and 156 were randomized to Healing Choices). The majority of the sample was non-Hispanic (272/282, 96%), White (239/314, 76%), married (251/320, 78.4%), and was on average 62.4 (SD 6.9) years old. Within both arms, there was a significant decrease in decisional conflict from baseline to 6 weeks postbaseline (Healium, P≤.001; Healing Choices, P≤.001), and a significant increase in satisfaction with one’s decision from 6 weeks to 3 months (Healium, P=.04; Healing Choices, P=.01). Within both arms, anxiety/tension (Healium, P=.23; Healing Choices, P=.27) and depression (Healium, P=.001; Healing Choices, P≤.001) decreased from baseline to 6 weeks, but only in the case of depression was the decrease statistically significant. CONCLUSIONS Healium, our brief decision aid focusing on treatment preference elicitation, is as successful in reducing decisional conflict as our previously tested comprehensive decision aid, Healing Choices, and has the added benefit of brevity, making it the ideal tool for integration into the physician consultation and electronic medical record. CLINICALTRIAL ClinicalTrials.gov NCT05800483; https://clinicaltrials.gov/study/NCT05800483